MarginsXMarginsX
Home › Markets › Health Care › AARD

Aardvark Therapeutics Inc. (AARD)

AARD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.26
-5.26% on the day
Market cap
$27.6M
Nano cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$57.6M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1774857/000119312526119770/0001193125-26-119770-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAARD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2025
SEC CIK0001774857
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$57.6M
Operating income-$62.7M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$47.1M
Total assets$117.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
10.8 months
$60.3M cash at September 30, 2026
Share count, 1 year
+0.5%
2025-11-03 to 2026-11-02
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
-$250K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-13
Cash and burn$60.3M cash; operating cash flow -$16.7M a quarter.Report 2026-09-30
Shares outstanding21,891,271 (2026-11-02); 21,773,272 a year earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., San Diego, California, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $145K, sold $395K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$19.2M-$13.5M$60.3MNo debt tags$010-Q 2026-11-13
Q2 2026
2026-06-30
$0-$14.4M-$17.6M$73.8MNo debt tags$010-Q 2026-08-11
Q1 2026
2026-03-31
$0-$21.6M-$18.9M$62.4MNo debt tags$010-Q 2026-05-07
Q4 2025
2025-12-31
$0-$17.6M-$16.8M$47.1MNo debt tags$010-K 2026-03-23
Q3 2025
2025-09-30
$0-$16.3M-$16.1M$39.3MNo debt tags$717K10-Q 2025-11-13
Q2 2025
2025-06-30
$0-$14.4M-$9.8M$26.0MNo debt tags$1.7M10-Q 2025-08-13
Q1 2025
2025-03-31
$0-$9.3M-$11.4M$26.5MNo debt tags$2.3M10-Q 2025-05-14
Q4 2024
2024-12-31
$717K-$8.8M-$7.7M$61.6MNo debt tags$2.4M10-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-03
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEF 14A2026-07-10

Source: SEC EDGAR submissions feed, 120 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+13.7%
1 month-67.1%
3 months-79.3%
Year to date-89.9%
1 year-87.8%
From 52-week high-91.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RMTIRockwell Medical Inc.$6.76-4.38%$26.9M
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M
BCTXBriaCell Therapeutics Corp. Common Shares$3.30-2.65%$28.8M
SCYXSCYNEXIS Inc.$2.91-9.35%$29.0M
ACETAdicet Bio Inc.$2.75-1.08%$25.7M
LITSLite Strategy Inc.$0.8565+1.16%$25.6M
PMNProMIS Neurosciences Inc. Common Shares (ON)$3.31+0.61%$29.8M
EDSAEdesa Biotech Inc. Common Shares$1.89-2.58%$25.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier